-- ヒンドゥスタン・コンポジット（NSE:HINDCOMPOS、BOM:509635）の連結純利益は、第4四半期に前年同期の6,070万インドルピーから1億1,700万インドルピーに増加した。これは、木曜日にインド証券取引所に提出された書類で明らかになった。 同社の株価は金曜日の取引で約6%上昇した。 3月31日締めの四半期の1株当たり利益は、前年同期の4.11ルピーから7.92ルピーに増加した。 第4四半期の営業収益は、8億9,150万ルピーから10億5,000万ルピーに増加した。 同社は、3月31日締めの会計年度について、1株当たり5ルピーの配当を発表した。
Related Articles
Asia
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
$ASX:NAB
Asia
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
$ASX:CUV
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF